25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CG Oncology, Inc. Common stock
Buy, Hold or Sell?

Let's analyze CG Oncology, Inc. Common stock together

I guess you are interested in CG Oncology, Inc. Common stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CG Oncology, Inc. Common stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CG Oncology, Inc. Common stock

I send you an email if I find something interesting about CG Oncology, Inc. Common stock.

1. Quick Overview

1.1. Quick analysis of CG Oncology, Inc. Common stock (30 sec.)










1.2. What can you expect buying and holding a share of CG Oncology, Inc. Common stock? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$8.29
Expected worth in 1 year
$14.70
How sure are you?
42.9%

+ What do you gain per year?

Total Gains per Share
$6.41
Return On Investment
18.9%

For what price can you sell your share?

Current Price per Share
$33.90
Expected price per share
$25.77 - $40.47
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of CG Oncology, Inc. Common stock (5 min.)




Live pricePrice per Share (EOD)
$33.90

2.2. Growth of CG Oncology, Inc. Common stock (5 min.)




Is CG Oncology, Inc. Common stock growing?

Current yearPrevious yearGrowGrow %
How rich?$552.3m$125.1m$174.3m58.2%

How much money is CG Oncology, Inc. Common stock making?

Current yearPrevious yearGrowGrow %
Making money-$16m-$9.5m-$6.4m-40.4%
Net Profit Margin-441,865.7%-1,489.2%--

How much money comes from the company's main activities?

2.3. Financial Health of CG Oncology, Inc. Common stock (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of CG Oncology, Inc. Common stock?

Welcome investor! CG Oncology, Inc. Common stock's management wants to use your money to grow the business. In return you get a share of CG Oncology, Inc. Common stock.

First you should know what it really means to hold a share of CG Oncology, Inc. Common stock. And how you can make/lose money.

Speculation

The Price per Share of CG Oncology, Inc. Common stock is $33.90. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of CG Oncology, Inc. Common stock.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in CG Oncology, Inc. Common stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $8.29. Based on the TTM, the Book Value Change Per Share is $1.60 per quarter. Based on the YOY, the Book Value Change Per Share is $0.63 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of CG Oncology, Inc. Common stock.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-0.8%-0.24-0.7%-0.14-0.4%-0.20-0.6%-0.20-0.6%
Usd Book Value Change Per Share-0.25-0.7%1.604.7%0.631.8%1.183.5%1.183.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.25-0.7%1.604.7%0.631.8%1.183.5%1.183.5%
Usd Price Per Share31.57-18.87-0.00-10.78-10.78-
Price to Earnings Ratio-27.83--17.76-0.00--10.15--10.15-
Price-to-Total Gains Ratio-126.30--59.34--59.34--59.34-
Price to Book Ratio3.81-2.24-0.00-1.28-1.28-
Price-to-Total Gains Ratio-126.30--59.34--59.34--59.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share33.9
Number of shares29
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.601.18
Usd Total Gains Per Share1.601.18
Gains per Quarter (29 shares)46.4734.33
Gains per Year (29 shares)185.86137.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101861760137127
203723620275264
305585480412401
407437340549538
509299200687675
60111511060824812
70130112920961949
8014871478010991086
9016731664012361223
10018591850013731360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.07.00.00.0%0.07.00.00.0%0.07.00.00.0%0.07.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.02.02.042.9%3.02.02.042.9%3.02.02.042.9%3.02.02.042.9%
Dividend per Share0.00.04.00.0%0.00.07.00.0%0.00.07.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share2.02.00.050.0%3.02.02.042.9%3.02.02.042.9%3.02.02.042.9%3.02.02.042.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CG Oncology, Inc. Common stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2501.602-116%0.626-140%1.184-121%1.184-121%
Book Value Per Share--8.2884.494+84%1.878+341%3.373+146%3.373+146%
Current Ratio--47.57134.266+39%3.180+1396%20.943+127%20.943+127%
Debt To Asset Ratio--0.0210.405-95%0.153-86%0.297-93%0.297-93%
Debt To Equity Ratio--0.0220.030-27%0.180-88%0.094-77%0.094-77%
Dividend Per Share----0%-0%-0%-0%
Eps---0.284-0.241-15%-0.143-49%-0.199-30%-0.199-30%
Free Cash Flow Per Share---0.242-0.259+7%-0.128-47%-0.203-16%-0.203-16%
Free Cash Flow To Equity Per Share---0.2411.638-115%0.076-420%0.968-125%0.968-125%
Gross Profit Margin--1.0001.000+0%1.000+0%1.000+0%1.000+0%
Market Cap2259102780.000+7%2104122915.5101257406923.878+67%-+100%718518242.216+193%718518242.216+193%
Net Profit Margin---170.288-4418.657+2495%-14.892-91%-2531.329+1386%-2531.329+1386%
Operating Margin---232.910-5203.679+2134%-16.703-93%-2980.689+1180%-2980.689+1180%
Operating Ratio--233.9105204.679-96%30.510+667%2987.178-92%2987.178-92%
Pb Ratio4.090+7%3.8092.238+70%-+100%1.279+198%1.279+198%
Pe Ratio-29.883-7%-27.829-17.756-36%--100%-10.146-64%-10.146-64%
Price Per Share33.900+7%31.57018.868+67%-+100%10.781+193%10.781+193%
Price To Free Cash Flow Ratio-35.010-7%-32.604-15.177-53%--100%-8.673-73%-8.673-73%
Price To Total Gains Ratio-135.620-7%-126.299-59.342-53%---59.342-53%-59.342-53%
Quick Ratio--91.18264.156+42%4.302+2020%38.504+137%38.504+137%
Return On Assets---0.033-0.050+50%-0.065+93%-0.056+69%-0.056+69%
Return On Equity---0.034-0.038+10%-0.076+123%-0.054+59%-0.054+59%
Total Gains Per Share---0.2501.602-116%0.626-140%1.184-121%1.184-121%
Usd Book Value--552359000.000299516500.000+84%125177000.000+341%224799571.429+146%224799571.429+146%
Usd Book Value Change Per Share---0.2501.602-116%0.626-140%1.184-121%1.184-121%
Usd Book Value Per Share--8.2884.494+84%1.878+341%3.373+146%3.373+146%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.284-0.241-15%-0.143-49%-0.199-30%-0.199-30%
Usd Free Cash Flow---16134000.000-17264750.000+7%-8535333.333-47%-13523571.429-16%-13523571.429-16%
Usd Free Cash Flow Per Share---0.242-0.259+7%-0.128-47%-0.203-16%-0.203-16%
Usd Free Cash Flow To Equity Per Share---0.2411.638-115%0.076-420%0.968-125%0.968-125%
Usd Market Cap2259102780.000+7%2104122915.5101257406923.878+67%-+100%718518242.216+193%718518242.216+193%
Usd Price Per Share33.900+7%31.57018.868+67%-+100%10.781+193%10.781+193%
Usd Profit---18902000.000-16039250.000-15%-9557333.333-49%-13261285.714-30%-13261285.714-30%
Usd Revenue--111000.000162500.000-32%64666.667+72%120571.429-8%120571.429-8%
Usd Total Gains Per Share---0.2501.602-116%0.626-140%1.184-121%1.184-121%
 EOD+5 -3MRQTTM+21 -13YOY+16 -175Y+18 -1610Y+18 -16

3.3 Fundamental Score

Let's check the fundamental score of CG Oncology, Inc. Common stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-29.883
Price to Book Ratio (EOD)Between0-14.090
Net Profit Margin (MRQ)Greater than0-170.288
Operating Margin (MRQ)Greater than0-232.910
Quick Ratio (MRQ)Greater than191.182
Current Ratio (MRQ)Greater than147.571
Debt to Asset Ratio (MRQ)Less than10.021
Debt to Equity Ratio (MRQ)Less than10.022
Return on Equity (MRQ)Greater than0.15-0.034
Return on Assets (MRQ)Greater than0.05-0.033
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of CG Oncology, Inc. Common stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.182
Ma 20Greater thanMa 5035.564
Ma 50Greater thanMa 10036.239
Ma 100Greater thanMa 20035.592
OpenGreater thanClose33.770
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About CG Oncology, Inc. Common stock

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Fundamental data was last updated by Penke on 2024-11-08 15:05:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit CG Oncology, Inc. Common stock earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare CG Oncology, Inc. Common stock to the Biotechnology industry mean.
  • A Net Profit Margin of -17,028.8% means that $-170.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CG Oncology, Inc. Common stock:

  • The MRQ is -17,028.8%. The company is making a huge loss. -2
  • The TTM is -441,865.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-17,028.8%TTM-441,865.7%+424,836.9%
TTM-441,865.7%YOY-1,489.2%-440,376.6%
TTM-441,865.7%5Y-253,132.9%-188,732.8%
5Y-253,132.9%10Y-253,132.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17,028.8%-115.9%-16,912.9%
TTM-441,865.7%-210.8%-441,654.9%
YOY-1,489.2%-214.5%-1,274.7%
5Y-253,132.9%-342.2%-252,790.7%
10Y-253,132.9%-464.5%-252,668.4%
4.3.1.2. Return on Assets

Shows how efficient CG Oncology, Inc. Common stock is using its assets to generate profit.

  • Above 5% is considered healthy but always compare CG Oncology, Inc. Common stock to the Biotechnology industry mean.
  • -3.3% Return on Assets means that CG Oncology, Inc. Common stock generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CG Oncology, Inc. Common stock:

  • The MRQ is -3.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.3%TTM-5.0%+1.7%
TTM-5.0%YOY-6.5%+1.4%
TTM-5.0%5Y-5.6%+0.6%
5Y-5.6%10Y-5.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.3%-11.1%+7.8%
TTM-5.0%-11.7%+6.7%
YOY-6.5%-11.3%+4.8%
5Y-5.6%-12.7%+7.1%
10Y-5.6%-14.3%+8.7%
4.3.1.3. Return on Equity

Shows how efficient CG Oncology, Inc. Common stock is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare CG Oncology, Inc. Common stock to the Biotechnology industry mean.
  • -3.4% Return on Equity means CG Oncology, Inc. Common stock generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CG Oncology, Inc. Common stock:

  • The MRQ is -3.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.4%TTM-3.8%+0.4%
TTM-3.8%YOY-7.6%+3.9%
TTM-3.8%5Y-5.4%+1.7%
5Y-5.4%10Y-5.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.4%-14.2%+10.8%
TTM-3.8%-15.8%+12.0%
YOY-7.6%-13.9%+6.3%
5Y-5.4%-18.5%+13.1%
10Y-5.4%-19.5%+14.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CG Oncology, Inc. Common stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient CG Oncology, Inc. Common stock is operating .

  • Measures how much profit CG Oncology, Inc. Common stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare CG Oncology, Inc. Common stock to the Biotechnology industry mean.
  • An Operating Margin of -23,291.0% means the company generated $-232.91  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CG Oncology, Inc. Common stock:

  • The MRQ is -23,291.0%. The company is operating very inefficient. -2
  • The TTM is -520,367.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-23,291.0%TTM-520,367.9%+497,077.0%
TTM-520,367.9%YOY-1,670.3%-518,697.7%
TTM-520,367.9%5Y-298,068.9%-222,299.0%
5Y-298,068.9%10Y-298,068.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23,291.0%-258.6%-23,032.4%
TTM-520,367.9%-318.3%-520,049.6%
YOY-1,670.3%-224.0%-1,446.3%
5Y-298,068.9%-386.5%-297,682.4%
10Y-298,068.9%-497.6%-297,571.3%
4.3.2.2. Operating Ratio

Measures how efficient CG Oncology, Inc. Common stock is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 233.91 means that the operating costs are $233.91 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of CG Oncology, Inc. Common stock:

  • The MRQ is 233.910. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5,204.679. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ233.910TTM5,204.679-4,970.770
TTM5,204.679YOY30.510+5,174.169
TTM5,204.6795Y2,987.178+2,217.501
5Y2,987.17810Y2,987.1780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ233.9102.594+231.316
TTM5,204.6793.360+5,201.319
YOY30.5103.299+27.211
5Y2,987.1784.788+2,982.390
10Y2,987.1786.528+2,980.650
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CG Oncology, Inc. Common stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if CG Oncology, Inc. Common stock is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 47.57 means the company has $47.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of CG Oncology, Inc. Common stock:

  • The MRQ is 47.571. The company is very able to pay all its short-term debts. +2
  • The TTM is 34.266. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ47.571TTM34.266+13.306
TTM34.266YOY3.180+31.085
TTM34.2665Y20.943+13.322
5Y20.94310Y20.9430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ47.5713.658+43.913
TTM34.2663.874+30.392
YOY3.1804.672-1.492
5Y20.9435.960+14.983
10Y20.9436.277+14.666
4.4.3.2. Quick Ratio

Measures if CG Oncology, Inc. Common stock is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare CG Oncology, Inc. Common stock to the Biotechnology industry mean.
  • A Quick Ratio of 91.18 means the company can pay off $91.18 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CG Oncology, Inc. Common stock:

  • The MRQ is 91.182. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 64.156. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ91.182TTM64.156+27.027
TTM64.156YOY4.302+59.854
TTM64.1565Y38.504+25.652
5Y38.50410Y38.5040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ91.1823.104+88.078
TTM64.1563.426+60.730
YOY4.3024.498-0.196
5Y38.5045.933+32.571
10Y38.5046.426+32.078
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CG Oncology, Inc. Common stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of CG Oncology, Inc. Common stock assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare CG Oncology, Inc. Common stock to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.02 means that CG Oncology, Inc. Common stock assets are financed with 2.1% credit (debt) and the remaining percentage (100% - 2.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CG Oncology, Inc. Common stock:

  • The MRQ is 0.021. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.405. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.021TTM0.405-0.384
TTM0.405YOY0.153+0.253
TTM0.4055Y0.297+0.108
5Y0.29710Y0.2970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0210.354-0.333
TTM0.4050.345+0.060
YOY0.1530.311-0.158
5Y0.2970.366-0.069
10Y0.2970.382-0.085
4.5.4.2. Debt to Equity Ratio

Measures if CG Oncology, Inc. Common stock is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare CG Oncology, Inc. Common stock to the Biotechnology industry mean.
  • A Debt to Equity ratio of 2.2% means that company has $0.02 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CG Oncology, Inc. Common stock:

  • The MRQ is 0.022. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.030. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.022TTM0.030-0.008
TTM0.030YOY0.180-0.151
TTM0.0305Y0.094-0.065
5Y0.09410Y0.0940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0220.398-0.376
TTM0.0300.437-0.407
YOY0.1800.378-0.198
5Y0.0940.452-0.358
10Y0.0940.495-0.401
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings CG Oncology, Inc. Common stock generates.

  • Above 15 is considered overpriced but always compare CG Oncology, Inc. Common stock to the Biotechnology industry mean.
  • A PE ratio of -27.83 means the investor is paying $-27.83 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CG Oncology, Inc. Common stock:

  • The EOD is -29.883. Based on the earnings, the company is expensive. -2
  • The MRQ is -27.829. Based on the earnings, the company is expensive. -2
  • The TTM is -17.756. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-29.883MRQ-27.829-2.054
MRQ-27.829TTM-17.756-10.073
TTM-17.756YOY--17.756
TTM-17.7565Y-10.146-7.610
5Y-10.14610Y-10.1460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-29.883-2.160-27.723
MRQ-27.829-2.428-25.401
TTM-17.756-3.145-14.611
YOY--3.304+3.304
5Y-10.146-6.080-4.066
10Y-10.146-6.625-3.521
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CG Oncology, Inc. Common stock:

  • The EOD is -35.010. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -32.604. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.177. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-35.010MRQ-32.604-2.406
MRQ-32.604TTM-15.177-17.427
TTM-15.177YOY--15.177
TTM-15.1775Y-8.673-6.504
5Y-8.67310Y-8.6730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-35.010-2.980-32.030
MRQ-32.604-3.295-29.309
TTM-15.177-3.682-11.495
YOY--4.523+4.523
5Y-8.673-8.162-0.511
10Y-8.673-9.239+0.566
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of CG Oncology, Inc. Common stock is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.81 means the investor is paying $3.81 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of CG Oncology, Inc. Common stock:

  • The EOD is 4.090. Based on the equity, the company is fair priced.
  • The MRQ is 3.809. Based on the equity, the company is fair priced.
  • The TTM is 2.238. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.090MRQ3.809+0.281
MRQ3.809TTM2.238+1.571
TTM2.238YOY-+2.238
TTM2.2385Y1.279+0.959
5Y1.27910Y1.2790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0901.869+2.221
MRQ3.8092.027+1.782
TTM2.2382.365-0.127
YOY-2.419-2.419
5Y1.2793.668-2.389
10Y1.2794.362-3.083
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of CG Oncology, Inc. Common stock.

4.8.3. Insider Transactions

Insiders are holding 7.048% of the shares of CG Oncology, Inc. Common stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-08-29Hong Fang SongSELL65045535.36
2024-01-29Corleen M RocheBUY200019
2024-01-29Decheng Capital Global Life ScBUY40000019
2024-01-29Hong Fang SongBUY26315719
2024-01-29Vijay KasturiBUY131519
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets564,330
Total Liabilities11,971
Total Stockholder Equity552,359
 As reported
Total Liabilities 11,971
Total Stockholder Equity+ 552,359
Total Assets = 564,330

Assets

Total Assets564,330
Total Current Assets563,864
Long-term Assets466
Total Current Assets
Cash And Cash Equivalents 25,158
Short-term Investments 527,722
Net Receivables 182
Other Current Assets 10,802
Total Current Assets  (as reported)563,864
Total Current Assets  (calculated)563,864
+/-0
Long-term Assets
Property Plant Equipment 413
Long-term Assets Other 53
Long-term Assets  (as reported)466
Long-term Assets  (calculated)466
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,853
Long-term Liabilities118
Total Stockholder Equity552,359
Total Current Liabilities
Short-term Debt 237
Accounts payable 4,491
Other Current Liabilities 7,125
Total Current Liabilities  (as reported)11,853
Total Current Liabilities  (calculated)11,853
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt118
Long-term Liabilities  (as reported)118
Long-term Liabilities  (calculated)118
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -165,778
Other Stockholders Equity 718,130
Total Stockholder Equity (as reported)552,359
Total Stockholder Equity (calculated)552,359
+/-0
Other
Capital Stock7
Cash and Short Term Investments 552,880
Common Stock Shares Outstanding 66,649
Liabilities and Stockholders Equity 564,330
Net Debt -24,803
Net Invested Capital 552,359
Net Working Capital 552,011
Property Plant and Equipment Gross 413
Short Long Term Debt Total 355



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
> Total Assets 
147,747
0
0
211,885
199,301
579,108
564,330
564,330579,108199,301211,88500147,747
   > Total Current Assets 
147,208
143,481
0
209,708
194,124
578,610
563,864
563,864578,610194,124209,7080143,481147,208
       Cash And Cash Equivalents 
88,143
-143,481
0
10,273
8,266
77,468
25,158
25,15877,4688,26610,2730-143,48188,143
       Short-term Investments 
55,338
286,962
0
193,476
179,408
489,040
527,722
527,722489,040179,408193,4760286,96255,338
       Net Receivables 
303
0
0
1
92
153
182
18215392100303
       Other Current Assets 
3,424
0
0
5,958
6,358
11,949
10,802
10,80211,9496,3585,958003,424
   > Long-term Assets 
539
-143,481
0
2,177
5,177
498
466
4664985,1772,1770-143,481539
       Property Plant Equipment 
506
0
0
550
491
445
413
41344549155000506
       Long-term Assets Other 
33
-143,481
0
1,627
4,686
53
53
53534,6861,6270-143,48133
> Total Liabilities 
22,570
0
0
319,908
14,511
10,168
11,971
11,97110,16814,511319,9080022,570
   > Total Current Liabilities 
15,429
0
0
11,703
14,254
9,984
11,853
11,8539,98414,25411,7030015,429
       Short-term Debt 
9,155
0
0
215
569
220
237
237220569215009,155
       Short Long Term Debt 
8,966
0
0
0
0
0
0
0000008,966
       Accounts payable 
985
0
0
1,961
3,242
4,658
4,491
4,4914,6583,2421,96100985
       Other Current Liabilities 
5,289
0
0
422
10,443
5,106
7,125
7,1255,10610,443422005,289
   > Long-term Liabilities 
7,141
0
0
308,205
257
184
118
118184257308,205007,141
       Long term Debt 
6,532
0
0
0
0
0
0
0000006,532
       Capital Lease Obligations 
446
0
0
517
461
404
355
35540446151700446
       Long-term Liabilities Other 
352
0
0
13
13
0
0
00131300352
> Total Stockholder Equity
125,177
125,177
0
-108,023
184,790
568,940
552,359
552,359568,940184,790-108,0230125,177125,177
   Common Stock
0
0
0
1
0
7
7
7701000
   Retained Earnings Total Equity0000000
   Accumulated Other Comprehensive Income -564,3300000-77,6930
   Capital Surplus 0000000
   Treasury Stock0000000
   Other Stockholders Equity 
3,642
0
0
5,802
6,842
715,807
718,130
718,130715,8076,8425,802003,642



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue204
Cost of Revenue-17
Gross Profit187187
 
Operating Income (+$)
Gross Profit187
Operating Expense-55,636
Operating Income-55,449-55,449
 
Operating Expense (+$)
Research Development45,752
Selling General Administrative9,901
Selling And Marketing Expenses17
Operating Expense55,63655,670
 
Net Interest Income (+$)
Interest Income0
Interest Expense-6,904
Other Finance Cost-13,808
Net Interest Income6,904
 
Pretax Income (+$)
Operating Income-55,449
Net Interest Income6,904
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-48,607-62,291
EBIT - interestExpense = -62,353
-48,607
-41,703
Interest Expense6,904
Earnings Before Interest and Taxes (EBIT)-55,449-41,703
Earnings Before Interest and Taxes (EBITDA)-55,432
 
After tax Income (+$)
Income Before Tax-48,607
Tax Provision-0
Net Income From Continuing Ops-48,607-48,607
Net Income-48,607
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses55,653
Total Other Income/Expenses Net6,842-6,904
 

Technical Analysis of CG Oncology, Inc. Common stock
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of CG Oncology, Inc. Common stock. The general trend of CG Oncology, Inc. Common stock is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine CG Oncology, Inc. Common stock's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CG Oncology, Inc. Common stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 34.93 < 35.12 < 40.47.

The bearish price targets are: 29.26 > 29.00 > 25.77.

Tweet this
CG Oncology, Inc. Common stock Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CG Oncology, Inc. Common stock. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CG Oncology, Inc. Common stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CG Oncology, Inc. Common stock. The current macd is -0.94265794.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the CG Oncology, Inc. Common stock price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for CG Oncology, Inc. Common stock. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the CG Oncology, Inc. Common stock price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
CG Oncology, Inc. Common stock Daily Moving Average Convergence/Divergence (MACD) ChartCG Oncology, Inc. Common stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CG Oncology, Inc. Common stock. The current adx is 20.61.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell CG Oncology, Inc. Common stock shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
CG Oncology, Inc. Common stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CG Oncology, Inc. Common stock. The current sar is 35.85.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
CG Oncology, Inc. Common stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CG Oncology, Inc. Common stock. The current rsi is 43.18. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
CG Oncology, Inc. Common stock Daily Relative Strength Index (RSI) ChartCG Oncology, Inc. Common stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CG Oncology, Inc. Common stock. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the CG Oncology, Inc. Common stock price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
CG Oncology, Inc. Common stock Daily Stochastic Oscillator ChartCG Oncology, Inc. Common stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CG Oncology, Inc. Common stock. The current cci is -64.79046416.

CG Oncology, Inc. Common stock Daily Commodity Channel Index (CCI) ChartCG Oncology, Inc. Common stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CG Oncology, Inc. Common stock. The current cmo is -13.75160091.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
CG Oncology, Inc. Common stock Daily Chande Momentum Oscillator (CMO) ChartCG Oncology, Inc. Common stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CG Oncology, Inc. Common stock. The current willr is -71.49075082.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that CG Oncology, Inc. Common stock is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
CG Oncology, Inc. Common stock Daily Williams %R ChartCG Oncology, Inc. Common stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of CG Oncology, Inc. Common stock.

CG Oncology, Inc. Common stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CG Oncology, Inc. Common stock. The current atr is 1.71510132.

CG Oncology, Inc. Common stock Daily Average True Range (ATR) ChartCG Oncology, Inc. Common stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CG Oncology, Inc. Common stock. The current obv is -9,661,680.

CG Oncology, Inc. Common stock Daily On-Balance Volume (OBV) ChartCG Oncology, Inc. Common stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CG Oncology, Inc. Common stock. The current mfi is 33.55.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
CG Oncology, Inc. Common stock Daily Money Flow Index (MFI) ChartCG Oncology, Inc. Common stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CG Oncology, Inc. Common stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

CG Oncology, Inc. Common stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CG Oncology, Inc. Common stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.182
Ma 20Greater thanMa 5035.564
Ma 50Greater thanMa 10036.239
Ma 100Greater thanMa 20035.592
OpenGreater thanClose33.770
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of CG Oncology, Inc. Common stock with someone you think should read this too:
  • Are you bullish or bearish on CG Oncology, Inc. Common stock? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about CG Oncology, Inc. Common stock? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CG Oncology, Inc. Common stock

I send you an email if I find something interesting about CG Oncology, Inc. Common stock.


Comments

How you think about this?

Leave a comment

Stay informed about CG Oncology, Inc. Common stock.

Receive notifications about CG Oncology, Inc. Common stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.